Vertex Pharma sees 2014 revenues below estimates

|About: Vertex Pharmaceuticals Inco... (VRTX)|By:, SA News Editor

Vertex Pharmaceuticals (VRTX -1.6%) is out with financial guidance ahead of its presentation at the JPMorgan Healthcare Conference on Tuesday.

Cash and equivalents as of FY13 end: $1.47B.

FY14 revenues seen at $570-600M versus consensus of $659.93B.

Kalydeco net revenues for FY14 projected at: $470-500M.

2014 projected opex: $900-950M. (PR)